It was observed that participants who experienced breakthrough infections with SARS-CoV-2 variants had lower levels of vaccine induced serum anti-Spike/RBD IgA at 2–4 weeks post-dose two compared to participants who did not experience an infection, while total IgG levels were comparable between groups (34). This evidence concerns the gene CHMP5 and infection.